Business

Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026

Financial Post · September 22, 2026 at 9:30 a.m.

OSAKA, Japan & CAMBRIDGE, Mass. -- Takeda ( TSE:4502/NYSE:TAK ) announced that new data from its oncology pipeline and portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026, in Madrid, Spain.

Key data will include a late-breaking abstract on arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343*) and two presentations on TAK-928 (Innovent R&D code: IBI363*).

Clinical and real-world analyses of ALUNBRIG ® (brigatinib) and FRUZAQLA ® (fruquintinib) will also be shared at the congress.

Read the full article on Financial Post ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.

Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026

More from Financial Post

Historic $250 Million Gift from John Paulson to Hebrew University Will Advance Engineering, Medicine, and Trauma Recovery

CGTN: From ‘potato capital’ to ‘token city’: How a city in north China is transforming

The Alberta referendum in focus: FP Video explores

Risk of an AI crunch for stock markets is rising

More in Business

Historic $250 Million Gift from John Paulson to Hebrew University Will Advance Engineering, Medicine, and Trauma Recovery

CGTN: From ‘potato capital’ to ‘token city’: How a city in north China is transforming

The Alberta referendum in focus: FP Video explores

Risk of an AI crunch for stock markets is rising

William Watson: In new pamphlet, U.K.’s Kemi Badenoch points the (right) way

Pipeline, major projects shows Ottawa’s commitment to Alberta, Smith says